W. Michael Korn: The FDA just granted marketing authorization for the Invitae Common Hereditary Cancers Panel.

W. Michael Korn, Chief Medical Officer for Oncology at Invitae, shared on LinkedIn:

“The FDA just granted marketing authorization for the Invitae Common Hereditary Cancers Panel. This is a first-in-class authorization for a DNA test capable of assessing predisposition to a multitude of cancer types – a fantastic testament to Invitae’s high-quality testing capabilities and the incredible people at Invitae who made this happen. The FDA decision is a major win for patients, providing access to high-quality testing with broad clinical utility.”

For details click here.
Source: W. Michael Korn/LinkedIn